首页> 美国卫生研究院文献>The Journal of Biological Chemistry >Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop
【2h】

Channel Gating Regulation by the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) First Cytosolic Loop

机译:囊性纤维化跨膜电导调节器(CFTR)第一胞质环对通道门控的调节

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

In this study, we present data indicating a robust and specific domain interaction between the cystic fibrosis transmembrane conductance regulator (CFTR) first cytosolic loop (CL1) and nucleotide binding domain 1 (NBD1) that allows ion transport to proceed in a regulated fashion. We used co-precipitation and ELISA to establish the molecular contact and showed that binding kinetics were not altered by the common clinical mutation F508del. Both intrinsic ATPase activity and CFTR channel gating were inhibited severely by CL1 peptide, suggesting that NBD1/CL1 binding is a crucial requirement for ATP hydrolysis and channel function. In addition to cystic fibrosis, CFTR dysregulation has been implicated in the pathogenesis of prevalent diseases such as chronic obstructive pulmonary disease, acquired rhinosinusitis, pancreatitis, and lethal secretory diarrhea (e.g. cholera). On the basis of clinical relevance of the CFTR as a therapeutic target, a cell-free drug screen was established to identify modulators of NBD1/CL1 channel activity independent of F508del CFTR and pharmacologic rescue. Our findings support a targetable mechanism of CFTR regulation in which conformational changes in the NBDs cause reorientation of transmembrane domains via interactions with CL1 and result in channel gating.
机译:在这项研究中,我们提供的数据表明,囊性纤维化跨膜电导调节剂(CFTR)的第一个胞质环(CL1)和核苷酸结合结构域1(NBD1)之间的鲁棒且特定的域相互作用,使离子运输能够以受控方式进行。我们使用共沉淀和ELISA建立了分子接触,并表明结合动力学并未因常见的临床突变F508del而改变。固有的ATPase活性和CFTR通道门控均被CL1肽严重抑制,这表明NBD1 / CL1结合是ATP水解和通道功能的关键要求。除囊性纤维化外,CFTR失调还与诸如慢性阻塞性肺疾病,后天性鼻-鼻窦炎,胰腺炎和致命性分泌性腹泻(例如霍乱)等流行疾病的发病机理有关。基于CFTR作为治疗靶标的临床相关性,建立了无细胞药物筛选机制,以鉴定NBD1 / CL1通道活性的调节剂,而独立于F508del CFTR和药理救助。我们的发现支持CFTR调控的一种可靶向机制,其中NBD的构象变化通过与CL1的相互作用引起跨膜结构域的重新定向,并导致通道门控。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号